loading
Schlusskurs vom Vortag:
$11.79
Offen:
$11.7
24-Stunden-Volumen:
100.69K
Relative Volume:
0.12
Marktkapitalisierung:
$640.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.90%
1M Leistung:
+23.61%
6M Leistung:
+1.29%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$11.54
$11.92
1-Wochen-Bereich:
Value
$10.87
$11.92
52-Wochen-Spanne:
Value
$7.80
$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name
Firmenname
Bicara Therapeutics Inc
Name
Telefon
617-785-8308
Name
Adresse
245 MAIN STREET, CAMBRIDGE
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
BCAX's Discussions on Twitter

Vergleichen Sie BCAX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BCAX
Bicara Therapeutics Inc
11.74 624.44M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.80 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.16 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.14 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.06 31.99B 3.81B -644.79M -669.77M -6.24

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-23 Hochstufung Wells Fargo Underweight → Equal Weight
2025-04-17 Eingeleitet Wells Fargo Underweight
2025-02-06 Eingeleitet Wedbush Outperform
2024-12-06 Eingeleitet H.C. Wainwright Buy
2024-11-05 Eingeleitet Rodman & Renshaw Buy
2024-10-08 Eingeleitet Cantor Fitzgerald Overweight
2024-10-08 Eingeleitet Morgan Stanley Overweight
2024-10-08 Eingeleitet Stifel Buy
2024-10-08 Eingeleitet TD Cowen Buy
Alle ansehen

Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten

pulisher
Jul 23, 2025

Is Bicara Therapeutics Inc. a good long term investmentUnprecedented profit potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Bicara Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Bicara Therapeutics Inc. stock priceHigh-velocity gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Bicara Therapeutics Inc. stockHigh-profit trading signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Bicara Therapeutics Inc. stock performs during market volatilityVolume Spike Monitors - Newser

Jul 22, 2025
pulisher
Jul 17, 2025

Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86 - Defense World

Jul 17, 2025
pulisher
Jul 15, 2025

Why Bicara Therapeutics Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Bicara Therapeutics Inc. stock price move sharplyInvestor Friendly Risk Reward - Newser

Jul 15, 2025
pulisher
Jul 08, 2025

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Yahoo Finance

Jul 08, 2025
pulisher
Jun 25, 2025

GAMMA Investing LLC Purchases 7,694 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 25, 2025
pulisher
Jun 12, 2025

Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals

Jun 12, 2025
pulisher
Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock - Investing.com

Jun 09, 2025
pulisher
Jun 06, 2025

Bicara Therapeutics Expands Boston Headquarters with New Lease - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

25,028 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Nuveen Asset Management LLC - Defense World

Jun 06, 2025

Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)

Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Bicara Therapeutics Inc-Aktie (BCAX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Meisner Lara
Chief Legal Officer
Jun 16 '25
Sale
10.43
15,829
165,096
0
$23.62
price up icon 3.28%
$36.59
price up icon 1.62%
$103.43
price up icon 0.09%
$27.66
price down icon 1.21%
$113.95
price down icon 0.57%
biotechnology ONC
$296.05
price up icon 0.44%
Kapitalisierung:     |  Volumen (24h):